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Abstract
Background: Appropriate diagnosis and treatment of latent 
tuberculosis infection (LTBI) play the most important role in 
the control of tuberculosis. This study aimed to determine the 
prevalence of LTBI among healthy tuberculosis unexposed 
children vaccinated with BCG using the tuberculin skin test 
(TST) and QuantiFERON TB Gold In-Tube (QFT-GIT) and 
comparing the agreement between the two tests.
Methods: A cross-sectional study was carried out between 
October 2009 and March 2010 in 24 schools and 11 daycare 
centers. A total of 967 children were divided into 15 age groups, 
with a minimum of 64 children per group.
Results: The prevalence rates of LTBI with TST were 3.8%, and 
2.2% with QFT-GIT. One case was positive in TST and QFT-GIT, 
20 cases were QFT-GIT positive, but TST negative and 36 cases 
were TST positive, but QFT-GIT negative, and finally, 910 cases 
were negative in both. There was poor agreement between 
TST and QFT-GIT (1.8%, 95%, CI: 0%-5.3%, k=0.007). The 
specificity of QFT-GIT in the BCG vaccinated, children aged 
1-15 years old, was 97.8% (97.8%, 95% CI: 96.8%-98.8%). 
After three months, 2/17 (11.8%) of those initially QFT-GIT 
negative converted, and 10/15 (66%) of those initially QFT-GIT 
positive reverted.
Conclusion: It seems that TST and QFT-GIT are not 
appropriate tests for the diagnosis of LTBI among healthy 
tuberculosis unexposed BCG vaccinated children. There was a 
low reproducibility rate of QFT-GIT. The cause of the the poor 
agreement requires further studies.
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Introduction
The World Health Organization (WHO) has estimated that 
approximately one-third of the world’s population is infected with 
Mycobacterium tuberculosis.1,2 This large population with latent 
infection poses a major challenge to global tuberculosis (TB) 
control and elimination campaigns. According to the latest global 
tuberculosis report, an estimated 8.6 million people developed 
TB and 1.3 million died from the disease.3 Between eight and 
nine million people develop TB every year.1,3,4 The trend of 
tuberculosis is decreasing in Iran and the tuberculosis incidence 
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rate was 13.7 per 100,000 population during 
2013 and 3.6% of all cases occurred under 
15 years old. The incidence and prevalence of 
TB varies among provinces in Iran, for example, 
higher in Golestan province in comparison with 
other provinces because of its ethnically varied 
population.5 During latent tuberculosis infection, 
the M. tuberculosis bacilli that persist in symptom-
free individuals can reactivate and cause active 
disease in about 10% of those infected over their 
lifetime.6-8 Treatment of latent infection can greatly 
reduce the likelihood that active tuberculosis will 
develop. Thus, it has the potential both to preserve 
the health of an individual person and to protect 
the health of the public by reducing the number 
of potential sources of infection.9The tuberculin 
skin test (TST) remained the only diagnostic tool 
for LTBI for decades. The results of TST have 
cross-reactions with the Bacillus Calmette-Guérin 
(BCG) vaccine and environmental mycobacteria, 
which lead to many false positives. Some other 
factors, such as deep injection and viral diseases, 
result in false negative responses. A new test for 
the diagnosis of LTBI, which is more specific than 
TST, and the result of which would not be affected 
by previous BCG vaccination, would be of more 
accurate use.10 QFT-GIT detects the in vitro cell-
mediated immune response to M. tuberculosis 
infection by measuring IFN-γ in the whole blood 
incubated with M. tuberculosis antigen [early 
secretory antigenic target 6 (ESAT-6), culture 
filtrate protein 10 (CFP-10) and another peptide 
from the TB antigen TB7.7 (Rv2654)]. An 
enzyme-linked immunosorbent assay (ELISA) 
detects the amount of IFN-γ, produced by the 
T cells.11 The antigens of ESAT-6 and CFP-10 are 
absent from all of the BCG vaccine strains and 
from the commonly encountered non-tuberculous 
mycobacteria (NTM), except M. kansasii, 
M. szulgai and M. marinum.12 Data about the 
performance of QFT-GIT in young children, 
especially those aged under 5 years, are limited. 
To the best of our knowledge, there has been no 
study on the use of QFT-GIT in low-risk children.13
In the present study, we set out to compare 
the performance of QFT-GIT, used for the 
detection of LTBI, with TST and to evaluate LTBI 
prevalence in children aged 1-15 years, who 
have been vaccinated with BCG at birth. LTBI 
is determined by positive TST or QFT-GIT in a 
person with no clinical presentation of active TB 
disease and no radiographic findings.
Patient and Methods
Study Design
A cross-sectional study was carried out on 
1-15 year-old children between October 2009 
and March 2010 at the Professor Alborzi Clinical 
Microbiology Research Center (affiliated 
with Shiraz University of Medical Sciences, 
Shiraz, Iran). The sample size was 967 children, 
divided into 15 age groups each consisting of at 
least 64 children. All participants were selected 
by stratified multistage random sampling in 
sex and age layers, from four different districts 
in 11 daycare centers, and 24 primary, junior 
high, and high schools. A minimum of 32 boys 
and 32 girls were included in each age group, 
with a BCG vaccination history at birth based 
on their vaccination documents. Children with 
acute febrile diseases, immunocompromised, 
on medications, positive exposure history to 
active tuberculosis patients, and the immigrants 
were excluded. Written informed consents from 
the parents were obtained and approved by 
the Ethics Committee of Shiraz University of 
Medical Sciences. In addition, questionnaires 
were filled out about age, location, nationality, 
health status, and history of nationwide at birth-
BCG vaccination. All patients with positive TST 
tests, no evidence of active disease, and no 
radiographic findings were considered as LTBI.
Tuberculin Skin Test
As for TST, 0.1 ml of purified protein derivative 
(PPD), Razi vaccine and serum research institute, 
Iran, equivalent to five tuberculin units of PPD 
solution was injected intradermally into the volar 
aspect of the forearm, and the mean vertical and 
transverse induration diameters were measured 
72 hours later. The positive interpretation of a 
TST is an induration of ≥10 mm in individuals.
QuantiFERON TB Gold In-Tube
From each participant, a 3 ml heparinized 
blood sample was collected by vein puncture 
for the QFT-GIT assay. IFN-γ responses to 
ESAT-6, CFP-10 and another peptide from the 
TB antigen TB7.7 (Rv2654) were measured 
by the QFT-GIT assay, according to the 
manufacturer’s instructions (Cellestis Ltd., 
Carnegie, Victoria, Australia), which involved 
two stages: (1) incubation of the whole blood 
with antigens and (2) measurement of IFN-γ 
production in the harvested plasma by ELISA. 
One ml of venous blood was added to each 
of the three heparin-containing tubes. One 
tube contained only heparin as negative (nil) 
control, another one contained T-cell mitogen 
phytohaemagglutinin as positive control, and the 
third tube had overlapping peptides representing 
the entire sequences of ESAT-6, CFP-10, and 
TB7.7. The tubes were incubated at 37°C and 
after 18-24 hours, they were centrifuged and the 
plasma was harvested and frozen at -70°C until 
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ELISA was performed. The amount of IFN-γ 
was quantified using QFT-GIT ELISA. The 
ELISA readout was analyzed using the QFT-GIT 
software. IFN-γ ≥0.35 IU/ml for QFT-GIT was 
considered as positive.
Reproducibility
To study the reproducibility of QFT-GIT, 
17 cases of those initially QFT-GIT negative/
TST positive and 15 cases of those initially QFT-
GIT positive/TST negative, were retested by 
both tests after 3 months.
Statistical Analysis
Collected data from the questionnaires and 
the results of TST and QFT-GIT were entered 
into SPSS, version 16. Agreement between 
the groups of results was assessed using 
k coefficients. Accordingly, Kappa values below 
0.1 indicate poor agreement, 0.1-0.4 indicates 
weak correlation, values of 0.41–0.60 indicate 
good agreement, and values above 0.6 shows 
strong agreement. Specificity of QFT-GIT 
was calculated and a P-value of <0.05 was 
considered significant.
Results
The Prevalence of LTBI with TST
Both the TST and QFT-GIT were administered 
to 967 individuals. Analysis of the collected data 
revealed that the prevalence of LTBI with TST 
among all the cases was 3.8% (37 positive/967 
with TST≥10 mm). All participants returned for 
TST interpretation. The highest rate was 7.8% in 
15-year old and the lowest rate (1.6%) was in the 
1-year old group. Using the Chi-square test, the 
LTBI prevalence rates of 3.7% in the 1-5 year old 
group, 3.4% in the 6-10 year old group and 4.4% in 
the 11-15 year old group by TST, indicate a direct 
correlation between age and LTBI prevalence 
among the children (Figure 1, Table 1). The 
prevalence rates by TST in males and females 
were 3.7% and 4%, respectively.
The Prevalence of LTBI with QFT-GIT
The prevalence of LTBI by QFT-GIT was 
2.2% (21 positive/967) Table 1. The prevalence 
rates of LTBI by QFT-GIT were 3.3% in males 
and 1% in females, thus the difference was 
significant (P≤0.05).
The Specificity and Agreement of QFT-GIT with 
TST
It is revealed that, one case was positive 
for TST and QFT-GIT, 20 cases were QFT-GIT 
positive but TST negative, and 36 cases were 
TST positive but QFT-GIT negative, and finally, 
910 cases were both QFT-GIT and TST negative 
Table 2. Comparison of the two tests by Kappa 
coefficient indicated a poor agreement between 
TST and QFT-GIT in the diagnosis of LTBI among 
low-risk children (1.8%, 95%, CI: 0%-5.3%) 
and (k=0.007). The specificity of QFT-GIT in 
the diagnosis of LTBI among the low-risk BCG 
vaccinated children aged 1-15 years was 97.8% 
(97.8%, 95%, CI: 96.8%-98.8%). Since there is 
no gold standard test for LTBI, we were not able 
to estimate the sensitivity of QFT-GIT.
Reproducibility of QFT-GIT
To evaluate the reproducibility of QFT-GIT, 32 
Individuals (17 negative and 15 positive at first 
visit) were retested after 3 months. The results 
showed that 2/17 (11.8%) of those initially 
QFT-GIT negative converted, and 10/15 (66%) of 
Figure 1 : There is a  relationship between age and prevalence of LTBI ( using Chi-square test ).
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those initially QFT-GIT positive reverted. Among 
the 10 individuals with reverted QFT-GIT results, 
the maximum and minimum IFN-γ responses 
at first visit were 1.081 IU/ml and 0.42 IU/ml, 
respectively. There was no significant difference 
between the IFN-γ mean values for the remaining 
5 persistent positive and the 10 reverted cases 
(0.71 vs. 0.81, P=0.983). Evaluation of the TST 
conversion rate revealed that 1/15 (6.7%) of 
those initially TST negative were converted.
One-year Follow-up of Children with LTBI
One year follow-up of children who considered 
as LTBI with TST of ≥10 mm, no evidence of 
active disease and no radiographic findings 
revealed no change to active TB disease.
Discussion
This study compared the TST and QFT-GIT in 
967 BCG-vaccinated children for the diagnosis 
of LTBI that selected among the general 
population. Most previous studies have been 
performed either in countries with low incidence 
tuberculosis, in adults, or in high-risk groups. 
The performance of QFT-GIT in children for 
the diagnosis of LTBI is not clear and remains 
challenging. There is limited data about the 
performance of QFT-GIT in children under 
17 years, especially in low-risk groups in regions 
where tuberculosis is endemic.13
In spite of the good agreement between 
TST and QFT-G in a few limited studies on 
high-risk children for the diagnosis of LTBI, 
in this study we found poor agreement in 
low-risk children (1.8%, 95%, CI: 0%-5.3%, 
k=0.007). In a study, among hospitalized Indian 
children, the agreement between the two 
tests was 100% (k=1.0) in BCG scar-negative 
children, as compared to 94% (k=0.63) in scar 
positive children.14Harada et al. and Carvalho 
et al. suggest that QFT-G may be used as a 
confirmatory test for TST.15,16 A meta-analysis 
indicated that the agreement between the two 
tests was 95.6% in German-born individuals 
younger than 40 years and not BCG-vaccinated. 
They concluded that the agreement of QFT-G 
and TST is excellent, with little potential that 
the TST is more likely to detect old infection 
than the QFT-G.17 Kariminia et al. also showed 
acceptable agreement between the two tests.18
In the present study, 20 cases were QFT-GIT 
positive but TST negative, 36 cases were TST 
positive but QFT-GIT negative and 910 cases 
were both QFT-GIT and TST negative. A few 
explanation can be found in literature for the 
disagreement and discordance between TST 
and GFT-GIT. In contrast to the TST, which 
remains positive for a protracted period after 
past- or clearance MTB infection, recent 
evidence suggests that QFT-GIT and T-SPOT TB 
assays detect more recent or ongoing infection. 
This may be because the IGRAs predominantly 
detects effector MTB-specific T cells in an 
overnight stimulation assay, whereas TST 
induration is measured at 48-72 hours, allowing 
Table 1: Results of TST and QFT-GIT tests in 1-15 years old BCG vaccinated children, Shiraz, Iran, 2010 (No=967)
TST results (n (%)) QFT-GIT results (%(n))
0-4 mm 5-9 mm 10-14 mm ≥15 mm Total Negative Positive Total
Age groups
1-5 yr 270 (82.8) 44 (13.5) 10 (3.1) 2 (0.6) 326 (100) 315 (97.2) 9 (2.8) 326 (100)
6-10 yr 257 (79.8) 54 (16.8) 7 (2.2) 4 (1.2) 322 (100) 317 (98.3) 5 (1.5) 322 (100)
11-15 yr 222 (69.6) 83 (26) 7 (2.2) 7 (2.2) 319 (100) 312 (97.8) 7 (2.2) 319 (100)
Total 749 (77.5) 181 (18.7) 24 (2.5) 13 (1.3) 967 (100) 946 (97.8) 21 (2.2) 967 (100)
Gender
Male 362 (74.8) 104 (21.5) 12 (2.5) 6 (1.2) 484 (100) 468 (96.7) 16 (3.3) 484 (100)
Female 387 (80) 77 (16) 12 (2.5) 7 (1.5) 483 (100) 478 (99) 5 (1) 483 (100)
Total 749 (77.5) 181 (18.7) 24 (2.5) 13 (1.3) 967 (100) 946 (97.8) 21 (2.2) 967 (100)
Location in Shiraz 
Region 1 193 (81.4) 36 (15.2) 5 (2.1) 3 (1.3) 237 (100) 232 (97.9) 5 (2.1) 237 (100)
Region 2 200 (86.2) 24 (10.3) 6 (2.6) 2 (0.9) 232 (100) 221 (95.3) 11 (4.7) 232 (100)
Region 3 195 (78.6) 44 (17.7) 6 (2.4) 3 (1.2) 248 (100) 248 (100) 0 248 (100)
Region 4 161 (64.4) 77 (30.8) 7 (2.8) 5 (2) 250 (100) 245 (98) 5 (2) 250 (100)
Total 749 (77.5) 181 (18.7) 24 (2.5) 13 (1.3) 967 (100) 946 (97.8) 21 (2.2) 967 (100)
Table 2: Correlation of TST and QFT-GIT tests in 
1-15 years old BCG vaccinated children, Shiraz, Iran, 2010
QFT-GIT results No. of cases with TST results
≥10 mm <10 mm Total
Positive (≥0.35 IU/ml) 1 20 21
Negative (<0.35 IU/ml) 36 910 946
Total 37 930 967
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for the expansion of memory T cell population.19 
Therefore, these assays would be important 
for outbreak and contact investigations, where 
it is important not to miss recently infected 
individuals. Moreover, negative IGRA results 
might be seen after eradication of TB infection. 
Lastly, it is possible that fluctuations in responses 
are due to concomitant infections such as NTM 
or helminthes and other host factors that may be 
influential.20,21
Since there is no gold standard test for LTBI, 
we could not estimate the sensitivity of QFT-
GIT, but the estimation of specificity in low-risk 
children with TST negative results was found 
to be 97.8% (97.8%, 95%, CI: 96.8%-98.8%). 
The findings indicate that QFT-GIT in BCG-
vaccinated, low-risk children has an excellent 
specificity similar to that in other reported studies. 
Menzies et al. and Pai et al. demonstrated by two 
meta-analysis studies that the interferon gamma 
release assay, especially QFT-G and QFT-GIT, 
have excellent specificity unaffected by BCG 
vaccination.22,23 Generally speaking, negative 
TST is taken as indicative of non-infected cases, 
except for special conditions. In the present 
study, 18 cases of those with a TST of 15 mm 
or greater were QFT-GIT negative, which can 
suggest the possible lack of sensitivity for QFT-
GIT, as has been reported in several previous 
studies. 24-26
In the present study, 2/17 (11.8%) of those 
initially QFT-GIT negative converted, and 
10/15 (66%) of those initially QFT-GIT positive 
reverted, were retested after 3 months. As 
reported, transient response to QFT-GIT is 
common, 6.3% conversion and 33% reversion for 
QFT-GIT, respectively, in their second visits after 
3 months.27 The present findings, are consistent 
with the previous reports22,23 and indicate the 
transient response of QFT-GIT. A high proportion 
of the participants with discordant IGRA+/TST-
reactions had spontaneous QFT-GIT reversion 
to negativity (66%). However, a higher reversion 
rate among children may also reflect the variability 
of IFN-γ responses during the adaptation of 
the cellular immune system.28 It also suggests 
that QFT-GIT may provide a more quantitative 
and dynamic measurement of cellular immune 
response than TST, which would be important for 
serial-testing studies.29 Because of no change in 
active TB disease after one year follow up, the TST 
reversion (6.7%) could be due to boosting effect, 
therefor boosting effect can play a confusing role 
in interpretation of TST results. A recent study in 
Guilan province of Iran demonstrated that non 
hospital employees had a higher age-associated 
booster reaction to the second tuberculin skin test 
than health care workers.30
Conclusion
According to the current study, it is concluded 
that, (i) there was poor agreement between QFT-
GIT and TST, (ii) there was a low reproducibility 
rate of QFT-GIT, and (iii) considering the low 
incidence of tuberculosis in the community 
under study, it seems that TST and QFT-GIT 
are not appropriate tests for the diagnosis of 
LTBI among healthy tuberculosis unexposed 
BCG vaccinated children. The cause of a poor 
agreement requires further studies.
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